It has been reported that anti-CD44 antibody-modified TSAIII-loaded liposomes (CD44-TSAIII-LP) could increase the circulation time, the bioavailability, the tumor-target accumulation, and the antitumor activity of TSAIII, demonstrating a potential agent for the therapeutic management of CD44-positive cancers [33]. The gene discussed is CD44; the disease is cancer.